TREGZI Wins FDA Approval: Blood Cancer Transplantation Moves Toward a More Precise Era of Cellular Reconstitution

For many patients with hematologic malignancies, allogeneic hematopoietic stem cell transplantation is a difficult threshold that may alter the course of disease. It is not only a matter of giving the patient a healthy donor’s hematopoietic system to take root again, but also of transferring a new immune force; that force can clear residual cancer cells, but it may also attack the patient’s own tissues, causing chronic graft-versus-host disease (GVHD). The significance of the U.S. FDA’s approval of TREGZI lies in the attempt to make this immune reconstitution more controllable.

TREGZI was developed by Orca Biosystems, and FDA product information lists it as an allogeneic regulatory T-cell immunotherapy composed of hematopoietic stem and progenitor cells (HSPC) and T cells. Its indication is for adult patients with hematologic malignancies who are undergoing matched donor hematopoietic stem cell transplantation and receiving myeloablative conditioning, with the aim of facilitating hematopoietic and immune reconstitution and improving chronic GVHD-free survival outcomes.

Compared with traditional allogeneic transplantation, TREGZI’s core concept is not simply to infuse donor cells, but to separate, prepare, and reinfuse different cell populations in a designed sequence. The prescribing information describes a single patient-specific dose as consisting of multiple infusion bags, including HSPC, regulatory T cells, conventional T cells, and diluent. This approach is intended to preserve the functions needed for post-transplant immune recovery while using regulatory T cells to reduce the likelihood of immune dysregulation.

FDA approval documents show that the biologics license application number for this case is STN BL 125868/0, with an approval effective date of June 30, 2026; although the replacement approval letter is dated July 1, the document explicitly states that the effective date remains unchanged. The approval letter also lists the review-related clinical trial numbers NCT04013685 and NCT05316701, and approves its manufacturing facility in Sacramento, California, indicating that this is not only recognition of a clinical concept, but also involves the production and release capabilities required for a highly personalized cellular product.

Orca Bio said the approval was based in part on the randomized, multicenter Phase 3 Precision-T study, which enrolled 187 patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or mixed-phenotype acute leukemia. The 12-month results announced by the company showed chronic GVHD-free survival of 78% in the TREGZI group and 38% in the traditional allogeneic transplant group; non-relapse mortality was 3% and 13%, respectively. These figures point to a clear clinical signal, but they should still be understood in the context of the trial population, donor matching conditions, and conditioning intensity.

Safety likewise cannot be obscured by the halo of approval. The risks listed in TREGZI’s prescribing information include graft failure, GVHD, infusion reactions, secondary malignancies or donor-derived malignancies, and transmission of infectious pathogens. These risks are not peripheral details of this type of treatment, but the core issues in hematopoietic stem cell transplantation itself that most require long-term management; for clinical teams, the new therapy brings a more refined tool, but also means that manufacturing, matching, scheduling, and follow-up all must be tightly coordinated.

The emergence of TREGZI takes blood cancer transplantation a step beyond “obtaining donor cells” toward “designing the composition of donor cells.” It does not eliminate the high-risk nature of transplantation, nor does it mean that all patients are suitable; the current approval scope is limited to specific adult hematologic malignancies and matched donor settings. Its true clinical value will depend on whether more centers can reproduce the efficacy and safety seen in the trial in everyday care, and whether this type of precision cellular therapy can maintain sufficiently stable quality beyond questions of accessibility and cost.